Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab (PACE in BC)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2014 by Vanderbilt University.
Recruitment status was:  Recruiting
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Douglas Brian Sawyer, Vanderbilt University Identifier:
First received: April 2, 2009
Last updated: December 1, 2014
Last verified: December 2014

RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers for increased risk of cardiac effects.

PURPOSE: This clinical trial is studying side effects involving the heart in women with breast cancer receiving doxorubicin and trastuzumab.

Condition Intervention
Breast Cancer
Cardiac Toxicity
Cardiovascular Complications
Biological: trastuzumab
Drug: doxorubicin hydrochloride
Genetic: polymorphism analysis
Other: laboratory biomarker analysis
Other: questionnaire administration
Procedure: assessment of therapy complications
Procedure: magnetic resonance imaging

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer)

Resource links provided by NLM:

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Change in cardiac function by echocardiogram [ Time Frame: 5 years ]
    change in cardiac function as measured by serial echocardiograms

Secondary Outcome Measures:
  • Overall feasibility [ Time Frame: 3 years ]

Biospecimen Retention:   Samples With DNA
Serum, Plasma, Mononuclear Cells

Estimated Enrollment: 200
Study Start Date: June 2008
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Persons with newly diagnosed breast cancer with planned anthracycline-based chemotherapy.


  • Diagnosed with breast cancer

    • Receiving treatment at Vanderbilt Ingram Cancer Center and other participating oncology practices in middle Tennessee and southern Kentucky
  • Starting a standard doxorubicin hydrochloride regimen for 4 courses

    • Also scheduled to receive trastuzumab (for patients enrolled in sub-study B only)
  • No presence of metastatic disease
  • Hormone receptor status not specified


  • Menopausal status not specified
  • Karnofsky performance status 60-100%
  • Not pregnant
  • Negative pregnancy test
  • Additional criteria for sub-study A (MRI):

    • Glomerular filtration rate ≥ 60 mL/min
    • No implanted electronic devices, cochlear implants, metallic implants, shrapnel or neurosurgical clips
    • No prior adverse reaction to gadolinium-based contrast agents
    • Must not exceed the weight limit or be too large to fit in the MRI scanner


  • See Disease Characteristics
  • No prior anthracycline chemotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00875238

Contact: Daniel Lenihan, MD 615-936-0335

United States, Kentucky
University of Louisville James Graham Brown Cancer Center Recruiting
Louisville, Kentucky, United States, 40202
Contact: Carrie G. Lenneman, MD, MSCI    502-852-7959   
Principal Investigator: Carrie G. Lenneman, MD, MSCI         
Sub-Investigator: Elizabeth C. Riley, MD         
Sub-Investigator: Dharamvir Jain, MD         
United States, Tennessee
Vanderbilt Heart One Hundred Oaks Active, not recruiting
Nashville, Tennessee, United States, 37204
MBCCOP - Meharry Medical College - Nashville Active, not recruiting
Nashville, Tennessee, United States, 37208
Vanderbilt-Ingram Cancer Center Active, not recruiting
Nashville, Tennessee, United States, 37232-6838
Sponsors and Collaborators
Vanderbilt University
National Cancer Institute (NCI)
Principal Investigator: Carrie G Lenneman, MD, MSCI Vanderbilt-Ingram Cancer Center & Univ. of Louisville
Principal Investigator: Daniel Lenihan, MD Vanderbilt University
Principal Investigator: Douglas B Sawyer, MD, PhD Vanderbilt University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Douglas Brian Sawyer, Professor of Medicine, Vanderbilt University Identifier: NCT00875238     History of Changes
Other Study ID Numbers: CDR0000613213
P30CA068485 ( US NIH Grant/Contract Award Number )
Study First Received: April 2, 2009
Last Updated: December 1, 2014

Keywords provided by Vanderbilt University:
cardiac toxicity
cardiovascular complications
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Pathologic Processes
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Radiation Injuries
Wounds and Injuries
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 25, 2017